SARS-CoV-2 Spike Protein Convergent Evolution: Impact of Virus Variants on Efficacy of COVID-19 Therapeutics and Vaccines: SpringerBriefs in Microbiology
Autor Daniele Focosien Limba Engleză Paperback – 12 oct 2021
Din seria SpringerBriefs in Microbiology
- 5% Preț: 352.76 lei
- 5% Preț: 319.99 lei
- 5% Preț: 354.68 lei
- Preț: 368.67 lei
- Preț: 372.24 lei
- Preț: 368.08 lei
- 5% Preț: 348.43 lei
- Preț: 366.95 lei
- 5% Preț: 351.83 lei
- Preț: 368.49 lei
- Preț: 371.85 lei
- 5% Preț: 348.96 lei
- Preț: 369.23 lei
- Preț: 372.60 lei
- Preț: 367.32 lei
- Preț: 366.78 lei
- Preț: 369.23 lei
- Preț: 370.73 lei
- Preț: 376.75 lei
Preț: 469.82 lei
Nou
Puncte Express: 705
Preț estimativ în valută:
89.92€ • 93.47$ • 74.49£
89.92€ • 93.47$ • 74.49£
Carte tipărită la comandă
Livrare economică 05-19 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783030873233
ISBN-10: 3030873234
Pagini: 136
Ilustrații: XIII, 136 p. 11 illus., 2 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.22 kg
Ediția:1st ed. 2021
Editura: Springer International Publishing
Colecția Springer
Seria SpringerBriefs in Microbiology
Locul publicării:Cham, Switzerland
ISBN-10: 3030873234
Pagini: 136
Ilustrații: XIII, 136 p. 11 illus., 2 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.22 kg
Ediția:1st ed. 2021
Editura: Springer International Publishing
Colecția Springer
Seria SpringerBriefs in Microbiology
Locul publicării:Cham, Switzerland
Cuprins
Chapter 1. Why the Spike protein is relevant for COVID19 therapeutics.- Chapter 2. SARS-CoV-2 variants.- Chapter 3. Conclusion.
Notă biografică
Dr. Daniele Focosi was born in Lucca (Italy) in 1980. He graduated in medicine with full grades in 2005 at the University of Pisa and completed specialization in hematology in 2009. Furthermore, he achieved a Ph.D. degree in clinical and fundamental virology in 2014 and a master’s degree in clinical trials in oncology-hematology in 2014.
Dr. Focosi has authored over 150 peer-reviewed manuscripts indexed on PubMed, for a total h-index of 30. He has been a fellow of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste and of the Collegio Ghislieri in Pavia, Italy. He is currently employed full time at the Pisa University Hospital.
He has given numerous oral and poster presentations at international medical congresses and is Member of the editorial board of 17 peer-reviewed journals.
He has received awards from the European Federation of Immunogenetics, the European Society for Organ Transplantation, the Italian Society for Hematology, the Italian Interregional Transplant Association, the Italian Bone Marrow Donor Association, the Italian Society for Experimental Hematology, and the Italian Society against Leukemia/Lymphoma/Myeloma.
Dr. Focosi has authored over 150 peer-reviewed manuscripts indexed on PubMed, for a total h-index of 30. He has been a fellow of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste and of the Collegio Ghislieri in Pavia, Italy. He is currently employed full time at the Pisa University Hospital.
He has given numerous oral and poster presentations at international medical congresses and is Member of the editorial board of 17 peer-reviewed journals.
He has received awards from the European Federation of Immunogenetics, the European Society for Organ Transplantation, the Italian Society for Hematology, the Italian Interregional Transplant Association, the Italian Bone Marrow Donor Association, the Italian Society for Experimental Hematology, and the Italian Society against Leukemia/Lymphoma/Myeloma.
Textul de pe ultima copertă
This book reviews the current knowledge of the globally circulating SARS-CoV-2 variants, highlights their distinct genetic characteristics and associated conformational changes in the viral spike protein, and profoundly discusses the mechanisms of convergent evolution that led to the rise of these mutated strains at different geographic regions during the Covid-19 pandemic. Furthermore, the book explores how these variants do and may impact the efficacy of established neutralizing antibody-based (nAb) vaccines and therapeutics by analysing latest in vivo and in vitro clinical data. Finally, the author discusses ways on how nAb Covid-19 treatment derived immune escape of SARS-CoV-2 could be minimized in the future.
Caracteristici
Provides a comprehensive overview on relevant SARS-CoV-2 variants Discusses the mechanisms of convergent evolution of the viral spike protein Explores how mutated strains impact the efficacy of Covid-19 vaccines